Coronavirus Update - 07th August 2020

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We remain open for business as usual and have started welcoming limited numbers of visitors to site

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Our work and case studies

Challenge: A client has developed new product to fulfil an unmet patient need. Pivotal clinical studies require highly sensitive, precise measurement of multiple insulin analogues from a small volume of plasma. Our existing methodologies have enabled successful proof of concept and non-regulated PK studies to be completed, but did not meet the precision necessary for regulatory acceptance. 

Customer:

European Biotech Company 

Outcome:

Following a demonstration in the autumn, a new mass spectrometer was purchased, installed and verified for insulins analysis within four months, in time to meet the client’s timeline for a key clinical trial. Analysis for the trial commenced in the spring, and the system is now analysing samples around the clock. 

Analysis of Insulins Case Study